Skip to main content
The drug industry's voice for manufacturing excellence
Production
Development
Information Technology
Compliance
Quality & Risk
Sections
Production
Development
Information Technology
Compliance
Quality & Risk
Facilities
Sectors
Special
Webinars
Podcasts
E-Handbooks
Industry News
Magazine Archives
Contact
Newsletter Subscription
Contact Us
Advertise
Follow us on
https://www.facebook.com/pages/Pharmaceutical-Manufacturing/140261116014887
http://www.linkedin.com/groups?gid=1813799
http://twitter.com/PharmaMfg
Editors' (re)View
Editors' (re)View
WuXi AppTec’s scarlet letter and the escalating US-China geopolitical conflict
Branded a “Chinese military” company by the Department of Defense, the CRDMO secured a legal victory last week against the 1260H designation, but the damage is done.
Aug. 11, 2026
Editors' (re)View
Brewing beer, drug ingredients, and making the US supply chain more resilient
Aug. 7, 2026
Editors' (re)View
Trump’s proposed tariffs on imported generic drugs would threaten US supply chain
July 24, 2026
Editors' (re)View
Why wasn’t WuXi Biologics added to DoD’s 1260H List like WuXi AppTec?
June 26, 2026
Editors' (re)View
Japan’s pressured pharma companies, peptides, and a growing reliance on CDMOs
May 29, 2026
Editors' (re)View
Eli Lilly navigates the uncharted waters of standing up multiple mega sites
May 22, 2026
Editors' (re)View
Drugmakers and CDMOs seize GLP-1 opportunity, invest in manufacturing facilities
March 6, 2026
Editors' (re)View
Cell and gene therapies take two steps forward, one step back
Feb. 6, 2026
Editors' (re)View
Optimistic 2026 outlook emerges for biopharma industry as JPM26 wraps up
Jan. 16, 2026
Looking for Something?
Load More Content
